David DiLillo
Company: Regeneron
Job title: Senior Director, Immuno-Oncology
Seminars:
Panel: Unveiling Distinctions: Evaluating TCR-T Cell Therapies, CAR-T, TCR Bispecifics, & Antibody Mimetics for Tailored Therapeutic Advancements 4:05 pm
• Quantifying Effectiveness: Comparing the relative affinities, potencies, and safety profiles of T-cell therapies, CAR-T, TCR bispecifics and antibody mimetics to discern their unique therapeutic characteristics • Strategic Suitability: Assessing the optimal indications and patient populations where each TCR modality excels • Beyond the Horizon: Exploring potential future modalities in the TCR therapy landscape, envisioning…Read more
day: Conference Day One
Targeting HLA/Peptides with Cell-Based Therapies: Target Discovery, Binder Generation & Benchmarking TCR-T Cells vs TCR Mimetic-Based CAR-T Cells 11:15 am
• Proteogenomic/Immunopeptidomic pipeline for HLA/peptide target discovery/validation • Robust in vivo platforms for TCR and TCRm antibody discovery • Benchmarking TCR-T vs TCR mimetic-based CAR-T: TCR and CAR-T cells demonstrate differential tumor control, reflecting co-stimulatory signaling requirementsRead more
day: Conference Day One
Panel: Unveiling Distinctions: Evaluating TCR-T Cell Therapies, CAR-T, TCR Bispecifics, & Antibody Mimetics for Tailored Therapeutic Advancements 3:00 pm
Quantifying Effectiveness: Comparing the relative affinities, potencies, and safety profiles of T-cell therapies, CAR-T, TCR bispecifics and antibody mimetics to discern their unique therapeutic characteristics Strategic Suitability: Assessing the optimal indications and patient populations where each TCR modality excels Beyond the Horizon: Exploring potential future modalities in the TCR therapy landscape, envisioning the untapped possibilities…Read more
day: DAY ONE TRACK 3 A
Targeting HLA/Peptides with Cell-Based Therapies: Target Discovery, Binder Generation & Benchmarking TCR-T Cells vs TCR Mimetic-Based CAR-T Cells 12:00 pm
Proteogenomic/Immunopeptidomic pipeline for HLA/peptide target discovery/validation Robust in vivo platforms for TCR and TCRm antibody discovery Benchmarking TCR-T vs TCR mimetic-based CAR-T: TCR and CAR-T cells demonstrate differential tumor control, reflecting co-stimulatory signaling requirementsRead more
day: DAY ONE TRACK 1 A